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Introduction {#sec005}
============

The nephrotoxicity of iodinated contrast media is well-known, and that is also the major cause of acute kidney injury (AKI). Formerly called contrast-induced nephropathy, it has now been called contrast-induced AKI (CI-AKI). The incidence of CI-AKI is high, with 12 to 50% morbidity \[[@pone.0231264.ref001]--[@pone.0231264.ref004]\]. Despite of its nephrotoxicity, the iodine-containing contrast medium is required to obtain good quality images. Therefore, its nephrotoxicity seems inevitable in clinical practice. Identified risk factors for CI-AKI are the following: impaired baseline renal function \[[@pone.0231264.ref005], [@pone.0231264.ref006]\], type and dose of contrast material \[[@pone.0231264.ref005], [@pone.0231264.ref007]\], conditions associated with reduced renal perfusion (such was heart failure \[[@pone.0231264.ref008]\], medications (angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blockers (ARB), non-steroidal anti-inflammatory drug (NSAID), diuretics, and metformin \[[@pone.0231264.ref009]\]), volume depletion like diarrhea or vomiting and sepsis. Despite of such knowledge on risk factors and the preventive measure with volume expansion, the incidence of CI-AKI remains high. This indicates other undiscovered risk factors for CI-AKI.

Bile acid or bilirubin with low water solubility can cause cast formation within the low pH microenvironment of distal nephrons. Bile cast cholemic nephrosis or bile nephrosis has been reported since 1953 \[[@pone.0231264.ref010]\]. Later related studies were done in rabbits 1957 \[[@pone.0231264.ref011]\], on tubular injury in 1958 \[[@pone.0231264.ref012]\], and on autopsy \[[@pone.0231264.ref013]\]. Since 2000, only a few studies have been reported on renal toxicity related to bile acid or bilirubin \[[@pone.0231264.ref014]--[@pone.0231264.ref016]\]. Bilirubin is an endogenous circulating antioxidant with protective role on kidney damages \[[@pone.0231264.ref017]\]. Also, bilirubin has ability anti-inflammatory, complete inhibitory and lipid-lowering properties\[[@pone.0231264.ref018]\]. Patients with Gilbert's syndrome may experience mild jaundice and the condition was recently shown to reduce all-cause mortality by half \[[@pone.0231264.ref019]\]. Hypobilirubinemia was reported in 2012 to be a possible risk factor for end-stage kidney disease (ESRD), independent of the estimated glomerular filtration rate (eGFR) \[[@pone.0231264.ref020]\]. A recent study also supported the protective role of hyperbilirubinemia on renal functions (0.5±0.2 vs. 0.7±0.3 mg/dl, p\<0.001) \[[@pone.0231264.ref021]\]. On the other hand, contradicting results were reported in another study as detailed below \[[@pone.0231264.ref022]\]. In that observational large hospital-based study of 2,678 adult outpatients, the total bilirubin was found to be inversely associated with eGFR in both non-diabetic (r = -0.17; p \< 0.0001) and diabetic patients (r = -0.14; p \< 0.05). Some issues remain controversial between serum bilirubin and renal function. First, there is no consensus regarding serum bilirubin in terms of its nephrotoxicity or renal protective role. Second, even if it is true for renal protection or nephrotoxicity, their effective cutoff values of hyperbilirubinemia remain unclear. Third, the effect of hyperbilirubinemia on CI-AKI was reported only in patients undergoing diagnostic angiography \[[@pone.0231264.ref023]\] or in coronary intervention \[[@pone.0231264.ref021]\] \[[@pone.0231264.ref024]\]. In the above clinical scenarios, the conditions are relatively simple. No studies have been done specifically on the relationship between serum bilirubin levels and CI-AKI after contrast-enhanced computed tomography (CCT). Fourth, the contrast volume, a possible risk factor for CI-AKI was not constant across studies. Finally, case numbers are not sufficiently large enough for adjusting confounding factors. Therefore, in the study, we determined the association between serum bilirubin and renal function after CCT (at a fixed volume of contrast volume, 100ml).

Methods and materials {#sec006}
=====================

Study design and patient population {#sec007}
-----------------------------------

We used in our hospital (Taichung Veterans General Hospital) a historical cohort that consisted data of 20,018 non-dialytic adult patients who had received the non-ionic iso-osmolar contrast medium, iodixanol (Visipaque, Chicago, IL, USA), for enhanced CT imaging during an approximately 15-year period (June 1, 2008 to March 31, 2015). The data recorded for each patient included a baseline serum level of creatinine and total bilirubin within two days before CCT. They were used to evaluate the association between serum bilirubin and renal outcome after CCT. Exclusion criteria were those with pre-existing AKI (defined according to KDIGO practice guideline\[[@pone.0231264.ref025]\]), with recent exposures to contrast media over the previous 30 days, volume of contrast medium not being to 100 ml (regular contrast volume for CCT), baseline serum levels of total bilirubin and creatinine within the two days before CCT not available, and post-contrast serum creatinine within one week after CCT not available.

Our study was approved by the institute review board of Taichung Veterans General Hospital approved this study (IRB TCVGH No:F15059). Patient informed consent was waived due to the pure data analysis nature of the study. There was no formal protocol for the prevention of contrast-induced nephropathy at this hospital over the study period.

Baseline data retrieval and definition {#sec008}
--------------------------------------

The baseline stages of chronic kidney diseases (CKD) was calculated using the equation of modification of diet in renal disease (MDRD) equation \[[@pone.0231264.ref026]\]: eGFR (ml/min per 1.73 m~2~) = 186\*SCr^-1.154^ \*Age^-0.203^\*0.742 (if female). Medical records of patients were screened for all comorbid conditions: such as, cardiovascular and cerebrovascular disease (cerebrovascular attack, coronary artery disease, peripheral arterial disease, and acute myocardial infarction), metabolic disease (diabetes mellitus, and hypertension), gastrointestinal bleeding, liver disease (cirrhosis, peritonitis, ascites and hepatoma), shock and malignancy (lung and colon cancer). Medications screened were ACEi, ARB, NSAID, aspirin, aminoglycoside, loop diuretics, steroid, statin, and H~2~-blocker (ranitidine and famotidine).

Outcome data retrieval and outcome definitions {#sec009}
----------------------------------------------

Primary outcome, PC-AKI, was defined according to the KDIGO practice guideline\[[@pone.0231264.ref025]\]: absolute increase of serum creatinine levels ≥0.3 mg/dl from baseline within 48 h, or ≥ 50% within 7 days after CCT \[[@pone.0231264.ref004]\]. Considering that urine volume had not been regularly collected, we therefore did not include the criterion of urine volume for AKI, as that was in the guideline of KDIGO. The secondary endpoint was the need of emergent hemodialysis within 30 days after CCT (as identified by the first recorded procedure of hemodialysis within 30 days after CCT). All the indication and timing for urgent hemodialysis for patients were the same as described below: refractory fluid overload even with diuretics, severe hyperkalemia (\>6.5 meq/L) even after medication, \>100 mg/dl of blood urea nitrogen, \>6 mg/dl of serum creatinine, metabolic acidosis (\<7.2), uremic encephalopathy, uremic bleeding and uremic pericarditis.

Patients were divided to three groups according to serum levels of total bilirubin: ≤1.2 mg/dl, 1.3\~2.0 mg/dl, and \>2.0 mg/dl. The first cutoff value was 1.2 mg/dl which just exceeded the normal range. Also, the Youden index was used to determine the cutoff value to predict AKI was set to \>1.2 mg/dl of total bilirubin within 30 days after CCT ([S1 Fig](#pone.0231264.s001){ref-type="supplementary-material"}). The other cutoff value of total bilirubin\> 2.0 mg/dl followed the Child--Pugh classification\[[@pone.0231264.ref027]\]. The incidence of AKI in patients with total bilirubin \> 2.0 mg/dl was also classified into different three liver conditions (cirrhosis, hepatoma and no cirrhosis or hepatoma) in [S2 Table](#pone.0231264.s004){ref-type="supplementary-material"}. Furthermore, the incidence of AKI in patients without any liver conditions was classified according to serum levels of total bilirubin in [S3 Table](#pone.0231264.s005){ref-type="supplementary-material"}.

Statistical analyses {#sec010}
--------------------

Quantitative data were expressed as mean ± standard deviation. Nominal and categorical variables were compared using the *Chi*-square likelihood ratio or Fisher exact test with bonferroni post-hoc analyses to detect differences between data pairs. Continuous variables were compared using the nonparametric Wilcoxon test. The stepwise multivariate logistic regression analysis was used to examine the independent association of PC-AKI with patient-related characteristics and comorbidities. In model 1, we adjusted for all comorbidities. They included cerebrovascular disease, coronary artery disease, peripheral arterial disease, and acute myocardial infarction, diabetes mellitus, hypertension, gastrointestinal bleeding, cirrhosis, peritonitis, ascites, hepatoma, shock lung and colon cancer. In model 2, in addition to adjusting for the above comorbidities, we further adjusted for the following: stage of CKD, hemoglobin, serum sodium, serum potassium, prothrombin time, international normalized ratio, the usage of aspirin, aminoglycoside, loop diuretics, ACEi, ARB, NSAID, and the use of fluid replacement \>1 liter on the day of CCT. The associations between serum bilirubin level (\>2.0 mg/dl) and the characteristics and risks of PC-AKI, and dialysis within 30 days after CCT were calculated by odds ratio (OR) and 95% confidence interval (CI). A two-sided p value of \<0.05 represented statistical significance. The SPSS software (Statistical Package for the Social Science, version 20.0, Armonk, NY, USA) was used for statistical analyses.

Results {#sec011}
=======

Initially, we recruited a total 20,018 who received CCT patients for this study. After exclusion, a total of 9,496 patients of these patients without missing data were enrolled in the final study cohort ([Fig 1](#pone.0231264.g001){ref-type="fig"}). Their baseline characteristics are list in [Table 1](#pone.0231264.t001){ref-type="table"}, according to three categories based on serum levels of total bilirubin (ie. ≤1.2, 1.3\~2.0, and \>2.0 mg/dl). Patients with higher levels of total bilirubin had the following characteristics: older (p = 0.012), more males (p\<0.001), lower serum albumin levels (p\<0.001), more with hyponatremia (p\<0.001), longer prothrombin time (p\<0.001), more metabolic acidosis (p\<0.001), fewer cerebrovascular attacks (p\<0.001), more cirrhosis (p\<0.001), more hepatoma (p\<0.001), fewer lung cancer (p\<0.001), more shocks (p\<0.001), more peritonitis (p\<0.001), more ascites (p\<0.001), and more gastrointestinal bleeding (p\<0.001). Patients with higher total bilirubin also received the medications as follow: less NSAIDs (p\<0.001), more aspirin (p\<0.001), more aminoglycosides (p\<0.001), more loop diuretics (p\<0.001), less ARB (p = 0.003), less steroid (p\<0.001), less statin (p\<0.001). They also received more fluid replacement (\>1 liter) (p = 0.009). Higher total bilirubin was associated with more PC-AKI (p\<0.001) and more incidence of urgent dialysis (p\<0.001).

![Algorithm of patient selection.](pone.0231264.g001){#pone.0231264.g001}

10.1371/journal.pone.0231264.t001

###### Baseline characteristics of patients.

![](pone.0231264.t001){#pone.0231264.t001g}

  Total bilirubin                           ≤1.2 (mg/dl)   1.3--2.0 (mg/dl)   \>2.0 (mg/dl)   All            *P* value
  ----------------------------------------- -------------- ------------------ --------------- -------------- -----------
  Numbers                                   7173           995                1368            9496           
  Age (years)                               64.63±16.31    62.62±16.66        65.88±15.89     64.91±16.29    0.012
  ≧65 years                                 3783 (52.7%)   527 (55.2%)        765 (55.9%)     5075 (53.4%)   0.051
  Female                                    2818 (39.3%)   301(31.5%)         415(30.3%)      3534 (37.2%)   \<0.001
  **Stages of CKD**                                                                                          \<0.001
  1                                         2730 (38.1%)   350 (36.6%)        541 (39.5%)     3621 (38.1%)   
  2                                         2292 (32.0%)   306 (32.0%)        371 (27.1%)     2969 (31.3%)   
  3a                                        866 (12.1%)    140 (14.7%)        176 (12.9)      1182 (12.4%)   
  3b                                        651 (9.1%)     91 (9.5%)          129 (9.4%)      871 (9.2%)     
  4                                         381 (5.3%)     49(5.1%)           106(7.7%)       536(5.6%)      
  5                                         253(3.5%)      19(2.0%)           45(3.3%)        317(3.3%)      
  **Laboratory data of blood**                                                                               
  Hemoglobin (g/dl)                         12.14±2.53     12.60±2.69         12.02±2.76      12.17±2.59     \<0.001
  Albumin (g/dl)                            3.47±0.72      3.29±0.75          3.12±0.75       3.40±0.74      \<0.001
  Calcium (mg/dl)                           8.04±1.63      7.84±1.66          7.88±1.54       8.00±1.62      \<0.001
  Sodium (meq/L)                            137.96±5.60    136.98±6.35        136.00±6.07     137.58±5.79    \<0.001
  Potassium (mg/dl)                         4.09±0.70      4.03±0.78          4.06±0.81       4.08±0.72      0.043
  Uric acid (mg/dl)                         6.59±2.56      7.72±3.83          6.70±3.14       6.68±2.74      0.043
  Prothrombin time (s)                      11.48±4.78     12.63±4.61         14.18±7.20      12.02±5.30     \<0.001
  pH                                        6.87±0.83      6.99±0.77          6.95±0.78       6.90±0.81      \<0.001
  HCO~3~^-^ (mmo/L)                         23.96±5.28     23.40±5.13         22.81±5.03      23.69±5.23     \<0.001
  **Comorbidity**                                                                                            
  Diabetes mellitus                         2116 (38.1%)   276 (28.9%)        422 (30.8%)     2814 (29.6%)   0.529
  Hypertension                              3529 (49.2%)   469(49.1%)         606 (44.3%)     4604 (48.5%)   0.004
  Cerebrovascular attack                    1114 (15.5%)   139 (14.6%)        132(9.6%)       1385 (14.6%)   \<0.001
  Peripheral arterial disease               178 (2.5%)     16 (1.7%)          28 (2.0%)       222 (2.3%)     0.224
  Cirrhosis                                 560 (7.8%)     208 (21.8%)        459 (33.6%)     1227 (12.9%)   \<0.001
  Hepatoma                                  501 (7.0%)     152 (15.9%)        358 (26.2%)     1011 (10.6%)   \<0.001
  Colon cancer                              796 (11.1%)    74 (7.7%)          101 (7.4%)      971 (10.2%)    \<0.001
  Lung cancer                               1466 (20.4%)   110 (11.5%)        139 (10.2%)     1715 (18.1%)   \<0.001
  Atrial fibrillation                       630 (8.8%)     124 (13.0%)        130 (10.2%)     884 (9.3%)     \<0.001
  Coronary arterial disease                 1179 (16.4%)   184 (19.3%)        204 (14.9%)     1567 (4.6%)    0.020
  Myocardial infarction                     346 (4.8%)     34 (3.6%)          58 (4.2%)       438 (4.6%)     0.168
  Shock                                     123 (1.7%)     24 (2.5%)          55 (4.0%)       202 (2.1%)     \<0.001
  Peritonitis                               128 (1.8%)     32 (3.4%)          72 (5.3%)       232 (2.4%)     \<0.001
  Ascites                                   70 (1.0%)      20 (2.1%)          66 (4.8%)       156 (1.6%)     \<0.001
  Gastrointestinal bleeding                 355 (4.9%)     65 (6.8%)          113(8.3%)       533(5.6)       \<0.001
  **Medication**                                                                                             
  Non-steroidal anti-inflammatory drugs     3666 (51.1%)   391 (40.9%)        503 (36.8%)     4560 (48.0%)   \<0.001
  Aspirin                                   1393 (19.4%)   180 (18.8%)        192 (14.0%)     1765 (18.6%)   \<0.001
  Aminoglycoside                            3092 (43.1%)   456 (47.7%)        686 (50.1%)     4234 (44.6%)   \<0.001
  Loop diuretics                            3866 (53.9%)   585 (61.3%)        888 (64.9%)     5339 (56.2%)   \<0.001
  Angiotensin-converting-enzyme inhibitor   643 (9.0%)     97 (10.2%)         120 (8.8%)      860 (9.1%)     0.446
  Angiotensin receptor blockers             1466 (20.4%)   178 (18.6%)        227 (16.6%)     1871 (19.7%)   0.003
  Steroid                                   1561 (21.8%)   155 (16.2%)        179 (13.1%)     1895 (20.2%)   \<0.001
  Statin                                    711 (9.9%)     77 (8.1%)          76 (5.6%)       864 (9.1%)     \<0.001
  Ranitidine                                654 (9.1%)     71 (7.4%)          116 (8.5%)      841 (8.9%)     0.198
  Famotidine                                1147 (16.0%)   149 (15.6%)        223 (16.3%)     1519 (16.0%)   0.902
  Fluid replacement \> 1000c.c.             1426 (19.9%)   199 (20.8%)        322 (23.5%)     1947 (20.5%)   0.009
  Acute kidney injury                       569 (7.9%)     89 (9.3%)          225 (16.4%)     883 (9.3%)     \<0.001
  Dialysis within 30 days                   304 (4.2%)     47 (4.9%)          98 (7.2%)       449 (4.7%)     \<0.001

Chi-square test and one-way ANOVA.

Patients in the group with total bilirubin\>2mg/dl had more AKI (16.4% vs. 9.3% vs. 7.9%) compared to the other two groups with lower levels (≤1.2 mg/dl (p\<0.001) and 1.3\~2.0 mg/dl (p\<0.001))([Fig 2A](#pone.0231264.g002){ref-type="fig"}). Similarly, patients with total bilirubin\>2mg/dl were prone to receive urgent hemodialysis compared to the other two groups of patients (≤1.2 mg/dl (p\<0.001) or 1.3\~2.0 mg/dl (p\<0.001)) ([Fig 2B](#pone.0231264.g002){ref-type="fig"}). No difference was found between the two groups with lower total bilirubin levels regarding AKI or the incidence of urgent dialysis.

![Renal outcomes after contrast-enhanced computed tomography in all patients divided by different serum levels of bilirubin.\
2A. Incidence of **acute kidney after** contrast-enhanced computed tomography (CCT) divided by different serum levels of total bilirubin. No statistical significance was noticed between the groups of ≤1.2 mg/dl and 1.3--2.0 mg/dl of serum bilirubin (7.9 vs. 6.3%). Differences are statistically significant between groups of ≤1.2 mg/dl and \>2.0 mg/dl of serum bilirubin (7.9 vs. 16.4%, p\<0.001); and between 1.3--2.0 mg/dl and \>2.0 mg/dl of serum bilirubin (9.3 vs. 16.4%, p\<0.001). 2B. Incidence of **urgent dialysis** within 30 days after contrast-enhanced computed tomography (CCT) divided by different serum levels of total bilirubin. No statistical significance was found between the groups of ≤1.2 mg/dl and 1.3--2.0 mg/dl of serum bilirubin (4.2 vs. 4.9%). Differences are statistically significant between groups of ≤1.2 mg/dl and \>2.0 mg/dl of serum bilirubin (4.2 vs. 7.2%, p\<0.001); and between 1.3--2.0 mg/dl and \>2.0 mg/dl of serum bilirubin (4.9 vs. 7.2%, p\<0.001).](pone.0231264.g002){#pone.0231264.g002}

Total bilirubin\>2mg/dl was associated with AKI (OR = 2.05, 1.72--2.45 of 95% CI), urgent dialysis (OR = 1.52, 1.14--2.02 of 95% CI) and mortality (OR = 1.82, 1.59--2.08 of 95% CI) ([Table 2](#pone.0231264.t002){ref-type="table"}) after adjusting all comorbidities in model 1 ([Table 1](#pone.0231264.t001){ref-type="table"}). After further adjusting for comorbidities, medications and laboratory data in model 2 ([Table 1](#pone.0231264.t001){ref-type="table"}), total bilirubin \>2 mg/dl was still associated with more AKI (OR = 1.89, 1.53--2.33 of 95% CI), dialysis (OR = 1.40, 1.01--1.95 of 95% CI) and mortality (OR = 1.63, 1.38--1.93 of 95% CI) in all patients ([Table 2](#pone.0231264.t002){ref-type="table"}). Therefore, total bilirubin \>2 mg/dl is an independent risk factor for AKI, dialysis and mortality after CCT in this cohort.

10.1371/journal.pone.0231264.t002

###### Association between serum bilirubin \> 2.0 mg/dL and the risk of acute kidney injury, dialysis within 30 days, and death after contrast-enhanced computerized tomography (CCT).

![](pone.0231264.t002){#pone.0231264.t002g}

                                              Odds Ratio   95%CI          *P* value
  ------------------------------------------- ------------ -------------- ------------------------------------------------
  Risk of acute kidney injury after CCT                                   
      Unadjusted                              2.23         (1.90--2.63)   \<0.001[\*\*](#t002fn003){ref-type="table-fn"}
      Adjusted, model 1                       2.05         (1.72--2.45)   \<0.001[\*\*](#t002fn003){ref-type="table-fn"}
      Adjusted, model 2                       1.89         (1.53--2.33)   \<0.001[\*\*](#t002fn003){ref-type="table-fn"}
  Risk of dialysis within 30 days after CCT                               
      Unadjusted                              1.71         (1.36--2.16)   \<0.001[\*\*](#t002fn003){ref-type="table-fn"}
      Adjusted, model 1                       1.52         (1.14--2.02)   0.005[\*\*](#t002fn003){ref-type="table-fn"}
      Adjusted, model 2                       1.40         (1.01--1.95)   0.044[\*](#t002fn002){ref-type="table-fn"}
  Risk of death after CCT                                                 
      Unadjusted                              1.98         (1.76--2.24)   \<0.001[\*\*](#t002fn003){ref-type="table-fn"}
      Adjusted, model 1                       1.82         (1.59--2.08)   \<0.001[\*\*](#t002fn003){ref-type="table-fn"}
      Adjusted, model 2                       1.63         (1.38--1.93)   \<0.001[\*\*](#t002fn003){ref-type="table-fn"}

Definition of acute kidney injury is an absolute increment of serum creatinine ≥0.3 mg/dl from baseline within 48 hours or ≥50% within 7 days after contrast-enhanced computerized tomography (CCT). Model 1, adjusted for the comorbidities listed in [Table 1](#pone.0231264.t001){ref-type="table"}. Model 2, adjusted for the stage of CKD, hemoglobin, serum sodium, serum potassium, prothrombin time, international normalized ratio, the usage of aspirin, aminoglycoside, loop diuretics, ACE inhibitors/ARB, non-steroidal anti-inflammatory drugs, the use of fluid replacement \> 1 liter on the day of CCT, plus covariates listed in Model 1.

\*: *p*\<0.05

\*\*: *p*\<0.01.

Compared to no cirrhosis or hepatoma, either with cirrhosis or hepatoma, patients are prone to have total bilirubin\>2.0mg/dl (34% vs. 10%, p\<0.001; 27.8% vs. 10%, p\<0.001; respectively) ([Fig 3](#pone.0231264.g003){ref-type="fig"}). Because total bilirubin\> 2 mg/dl is more common in patients with liver conditions, we further analyzed the association between total bilirubin \>2 mg/dl and renal outcome in patients with baseline liver diseases ([Table 3](#pone.0231264.t003){ref-type="table"}). The total bilirubin\> 2 mg/dl was still associated with more AKI (OR = 3.50, 2.14--5.72 of 95% CI), and mortality (OR = 2.21, 1.58--3.11 of 95% CI) in patients with cirrhosis. Similarly, total bilirubin \>2 mg/dl was also associated with more AKI (OR = 3.24, 1.89--5.56 of 95% CI), and mortality (OR = 2.41, 1.65--3.50 of 95% CI) in patients with hepatoma ([Table 3](#pone.0231264.t003){ref-type="table"}). The ORs for AKI, dialysis and mortality are more significant in the cirrhosis group (3.50 vs. 1.89, 1.55 vs. 1.40; 2.21 vs. 1.63) ([Table 3](#pone.0231264.t003){ref-type="table"}) or the hepatoma group (3.24 vs. 1.89; 1.35 vs. 1.40; 2.41 vs. 1.63) ([Table 3](#pone.0231264.t003){ref-type="table"}) than in whole patients group ([Table 2](#pone.0231264.t002){ref-type="table"}). In summary, patients with worse liver conditions (total bilirubin\>2 mg/dl) in baseline cirrhosis or hepatoma ([Table 3](#pone.0231264.t003){ref-type="table"}) had higher and additional risk of worse renal outcomes than whole population ([Table 2](#pone.0231264.t002){ref-type="table"}).

![Incidence of serum bilirubin \> 2.0 mg/dl in patients with different liver conditions.\
Differences are statistically significant between groups of serum bilirubin \> 2.0mg/dl in patients with cirrhosis and without liver conditions (34 vs. 10%, p\<0.001), and between groups of patients with hepatoma and without liver conditions (27.8 vs. 10%, p\<0.001).](pone.0231264.g003){#pone.0231264.g003}

10.1371/journal.pone.0231264.t003

###### Association between serum bilirubin \> 2.0 mg/dl and the risk of acute kidney injury, dialysis within 30 days and death after contrast-enhanced computerized tomography (CCT) in patients with liver cirrhosis and liver cancer.

![](pone.0231264.t003){#pone.0231264.t003g}

                                                                       Odds Ratio   95%CI    *P* value   
  -------------------------------------------------------------------- ------------ -------- ----------- ------------------------------------------------
  Patients with **liver cirrhosis** and serum bilirubin \> 2.0 mg/dl                                     
      Risk of acute kidney injury after CCT                                                              
          Unadjusted                                                   3.55         (2.47-   5.09)       \<0.001[\*\*](#t003fn003){ref-type="table-fn"}
          Adjusted, model 1                                            3.69         (2.50-   5.44)       \<0.001[\*\*](#t003fn003){ref-type="table-fn"}
          Adjusted, model 2                                            3.50         (2.14-   5.72)       \<0.001[\*\*](#t003fn003){ref-type="table-fn"}
      Risk of dialysis within 30 days after CCT                                                          
          Unadjusted                                                   1.48         (0.94-   2.33)       0.093
          Adjusted, model 1                                            1.58         (0.91-   2.75)       0.103
          Adjusted, model 2                                            1.55         (0.77-   3.11)       0.220
      Risk of death within 30 days after CCT                                                             
          Unadjusted                                                   2.29         (1.80-   2.91)       \<0.001[\*\*](#t003fn003){ref-type="table-fn"}
          Adjusted, model 1                                            2.36         (1.81-   3.08)       \<0.001[\*\*](#t003fn003){ref-type="table-fn"}
          Adjusted, model 2                                            2.21         (1.58-   3.11)       \<0.001[\*\*](#t003fn003){ref-type="table-fn"}
  Patients with **liver cancer** and serum bilirubin \> 2.0 mg/dl                                        
      Risk of acute kidney injury after CCT                                                              
          Unadjusted                                                   3.50         (2.36-   5.18)       \<0.001[\*\*](#t003fn003){ref-type="table-fn"}
          Adjusted, model 1                                            3.47         (2.26-   5.33)       \<0.001[\*\*](#t003fn003){ref-type="table-fn"}
          Adjusted, model 2                                            3.24         (1.89-   5.56)       \<0.001[\*\*](#t003fn003){ref-type="table-fn"}
      Risk of dialysis within 30 days after CCT                                                          
          Unadjusted                                                   1.37         (0.76-   2.48)       0.296
          Adjusted, model 1                                            1.33         (0.67-   2.66)       0.413
          Adjusted, model 2                                            1.35         (0.52-   3.52)       0.536
      Risk of death within 30 days after CCT                                                             
          Unadjusted                                                   2.33         (1.79-   3.03)       \<0.001[\*\*](#t003fn003){ref-type="table-fn"}
          Adjusted, model 1                                            2.26         (1.70-   3.00)       \<0.001[\*\*](#t003fn003){ref-type="table-fn"}
          Adjusted, model 2                                            2.41         (1.65-   3.50)       \<0.001[\*\*](#t003fn003){ref-type="table-fn"}

Definition of acute kidney injury is an absolute increment of serum creatinine ≥0.3 mg/dl from baseline within 48 hours or ≥50% within 7 days after contrast-enhanced computerized tomography (CCT). Model 1, adjusted for the comorbidities listed in [Table 1](#pone.0231264.t001){ref-type="table"}. Model 2, adjusted for the stage of CKD, hemoglobin, serum sodium, serum potassium, prothrombin time, international normalized ratio, the usage of aspirin, aminoglycoside, loop diuretics, ACE inhibitors/ARB, non-steroidal anti-inflammatory drugs, the use of fluid replacement \> 1 liter on the day of CCT, plus covariates listed in Model 1.

\*: *p* \<0.05

\*\*: *p* \<0.01

The incidence of AKI in total bilirubin\> 2 mg/dl according to different baseline liver conditions were shown in [Fig 4](#pone.0231264.g004){ref-type="fig"}. In patients with cirrhosis ([Fig 4A](#pone.0231264.g004){ref-type="fig"}), hepatoma ([Fig 4B](#pone.0231264.g004){ref-type="fig"}), or without cirrhosis or hepatoma ([Fig 4C](#pone.0231264.g004){ref-type="fig"}), patients with total bilirubin \>2.0mg/dl also had more CI-AKI than patients lower levels of total bilirubin (p\<0.001). This result also indicated that total bilirubin \> 2 mg/dl was independent risk factors for CI-AKI in different baseline liver conditions. In patients with total bilirubin\> 2 mg/dl (n = 1368), baseline characteristics were shown in [S2 Table](#pone.0231264.s004){ref-type="supplementary-material"} according to baseline liver conditions. Moreover, patients with total bilirubin \> 2 mg/dl but without cirrhosis or hepatoma (n = 7826) were also shown [S3 Table](#pone.0231264.s005){ref-type="supplementary-material"}. Non-cirrhosis or hepatoma related hyperbilirubinemia (\>2 mg/dl) was associated with older age (p\<0.001), hypoalbuminemia (p\<0.001), longer prothrombin time (p\<0.001), more metabolic acidosis (p\<0.001), less lung cancer (p\<0.001), less cerebrovascular attack (p\<0.001), less NSAID (p\<0.001) and steroid usage (p\<0.001), more aminoglycoside usage (p\<0.001), and more fluid replacement (p = 0.017).

![Acute kidney injury after contrast-enhanced computed tomography (CCT) in patients with different liver conditions divided by different serum levels of total bilirubin.\
4A. Incidence of **acute kidney injury** after contrast-enhanced computed tomography (CCT) divided by different serum levels of total bilirubin in patients with **cirrhosis**. No statistical significance was noticed between the groups of ≤ 1.2 mg/dl and 1.3--2.0 mg/dl of serum bilirubin (6.6 vs. 7.2%). Differences are statistically significant between groups of ≤ 1.2 mg/dl and \> 2.0 mg/dl of serum bilirubin (6.6 vs. 20.5%, p\<0.001), and between 1.3--2.0 mg/dl and \>2.0 mg/dl of serum bilirubin (7.2 vs. 20.5%, p\<0.001). 4B. Incidence of **acute kidney injury** after contrast-enhanced computed tomography (CCT) divided by different serum levels of total bilirubin in patients with **hepatoma**. No statistical significance was noticed between the groups of ≤1.2 mg/dl and 1.3--2.0 mg/dl of serum bilirubin (6.4% vs. 9.2%). Differences are statistically significant between groups of ≤ 1.2 mg/dl and \> 2.0 mg/dl of serum bilirubin (6.4 vs. 20.9%, p\<0.001), and between 1.3--2.0 mg/dl and \>2.0 mg/dl of serum bilirubin (9.2 vs. 20.9%, p\<0.001). 4C. Incidence of **acute kidney injury** after contrast-enhanced computed tomography (CCT) divided by different serum levels of total bilirubin in patients without **hepatoma or cirrhosis**. No statistical significance was noticed between the groups of ≤1.2 mg/dl and 1.3--2.0 mg/dl of serum bilirubin (8.1% vs. 9.6%). Differences are statistically significant between groups of ≤ 1.2 mg/dl and \> 2.0 mg/dl of serum bilirubin (8.1 vs. 13.4%, p\<0.001), and between 1.3--2.0 mg/dl and \>2.0 mg/dl of serum bilirubin (9.6 vs. 13.4%, p\<0.001).](pone.0231264.g004){#pone.0231264.g004}

Post-CCT mortality is shown in [Fig 5](#pone.0231264.g005){ref-type="fig"}. Patients with total bilirubin levels ≤2.0 mg/dl and without AKI had the lowest mortality. For patients with either total bilirubin \>2.0mg/dl or with AKI, mortality was higher (15% vs. 5.9%, p\<0.001; 26.7% vs. 5.9%, p\<0.001). Patients with simultaneously AKI and total bilirubin \>2.0mg/dl had the highest mortality (41.8% vs. 5.9%, p\<0.001).

![Compared to no AKI and ≤ 2.0 mg/dl of serum bilirubin, patient mortality within 30 days after contrast-enhanced computed tomography (CCT) increased if AKI had occurred (26.7%, p\<0.001) or \> 2.0 mg/dl of serum bilirubin (15.0%, p\<0.001).\
Patients with both AKI and \> 2.0 mg/dl of serum bilirubin had the highest risk of mortality (41.8%, p\<0001).](pone.0231264.g005){#pone.0231264.g005}

Discussion {#sec012}
==========

We conduct this study to elucidate the association between serum total bilirubin and CI-AKI in patients undergoing CCT. Previous studies on this issue only involved in patients undergoing angiography for coronary \[[@pone.0231264.ref021]\] \[[@pone.0231264.ref024]\] or with peripheral arterial intervention \[[@pone.0231264.ref023]\]. Our study is the first on patients undergoing CCT and it has largest of cases focusing on the association between total bilirubin and renal function. Previous studies were focused on relatively simple condition likely due to small numbers of cases and hard to adjust for confounding factors. Patients underwent CCT have more complicated comorbidities (e.g. shock, bleeding, cirrhosis, and hepatoma) and therefore more cases are required to analyze common clinical scenarios of CI-AKI after CCT than those after vascular intervention. Negative or inconclusive results on the relationship between bilirubin and renal functions were observed mostly in patients with multiple comorbidities such as hemorrheological disorders, infectious diseases, and decompensated heart failure. These conditions confound the effect of bilirubin on prognosis and the results obtained should be interpreted with caution. The importance of this study is the large number of cases (\>9,000) so that all comorbidities and any other confounding factors could be adjusted for.

Mild elevation of serum bilirubin has renal protective funtion related to antioxidative effects of bilirubin \[[@pone.0231264.ref017]--[@pone.0231264.ref019], [@pone.0231264.ref021], [@pone.0231264.ref028]--[@pone.0231264.ref034]\]. Bilirubin can bind to albumin \[[@pone.0231264.ref017]\] and exhibits protein anitoxidative, anti-inflammatory, complete inhibitory and lipid-lowering properties \[[@pone.0231264.ref018]\]. It may also protect against all-cause mortality and CV diseases. For patients of Gilbert's syndrome with mild jaundice the incidence of all-cause mortality is lowerd by half \[[@pone.0231264.ref019]\]. In a Korean study on a cohort (n = 1,458) with primary IgA nephropathy \[[@pone.0231264.ref028]\], quartile levels of bilirubin of patients were divided into: \<0.4 mg/dL, 0.4--0.5 mg/dL, 0.6--0.7 mg/dL, and \>0.8 mg/d. They found that the level of bilirubin was negatively associated with the incidence of ESRD. In another Korean study (1,363 patients) \[[@pone.0231264.ref029]\], total serum bilirubin was positively associated with eGFR and negatively associated with proteinuria. But their highest level of total bilirubin was only 0.77±0.22 mg/dl. In 2012, 544 patients receiving coronary intervention experienced fewer CI-AKI with higher serum levels of bilirubin \[[@pone.0231264.ref021]\]. The dovodomg values of bilirubin were ≤0.5 mg/dl, 0.5--0.7 mg/dl, and \>0.7 mg/dl. Another study druing the same year showed that hypobilirubinemia is a possible risk factor of ESRD \[[@pone.0231264.ref020]\]. Their dividing values of bilirubin were \<0.55, 0.59, 0.56, 0.47, and 0.36 mg/dl \[[@pone.0231264.ref020]\]. Bilirubin could attenuate cyclosporine-induced nephropathy of tubular injury by inhibiting oxidative stress and apoptosis in HK-2 cells \[[@pone.0231264.ref033]\]. With higher levels of bilirubin, the greater suppression on oxidative stress might attenuate the progression of CKD \[[@pone.0231264.ref017], [@pone.0231264.ref034]\]. Importantly, all the above clinical studies are in support of renal protection by bilirubin were based on mild elevation of bilirubin levels oftern within normal range (\<1.2 mg/dl). That is why one of cutoff levels of bilirbuin in our study is 1.2 mg/dl.

However, not all studies supported the same conclusion \[[@pone.0231264.ref014], [@pone.0231264.ref022], [@pone.0231264.ref035]--[@pone.0231264.ref042]\]. For example, Targher et al\[[@pone.0231264.ref022]\], did an observational study with 2,678 patients and they found that total bilirubin was inversely associated with eGFR in both non-diabetic (r = -0.17; p\<0.0001) and diabetic patients (r = -0.14; p\<0.05). In another study, the increased total bilirubin levels are independently associated with decreasing eGFR \[[@pone.0231264.ref035]\]. The authors hypothesized that the discrepancy in conclusion with the mainstream literature maybe due to nonalcoholic fatty liver disease \[[@pone.0231264.ref035]\]. Similarly, the benefits of hyperbilirubinemia might be confounded by other factors like: cholemic nephrosis \[[@pone.0231264.ref014], [@pone.0231264.ref038]\], cholestasis \[[@pone.0231264.ref039]\], infection with malaria \[[@pone.0231264.ref040], [@pone.0231264.ref041]\] and spontaneous bacterial peritonitis \[[@pone.0231264.ref036]\], and heart failure \[[@pone.0231264.ref042]\]. On the contrary, in patients with nonfulminant hepatitis A, lower levels of bilirubin are associated with fewer \[[@pone.0231264.ref037]\]. In the vent of hepatopathy, total bilirubin level is no longer associated with the protective effects from cardiovascular disease. Such findings highlighted the problematic use of total bilirubin measures in any investigation of the protective effects of bilirubin \[[@pone.0231264.ref043]\]. These studies with negative findings also indicated that patients with severe liver disease are more likely to develop hepatic encephalopathy and hepatorenal syndrome. That result is consistent with ours in that total bilirubin level \>2 mg/dl was mostly in patients with cirrhosis or hepatoma and total bilirubin \>2.0mg/dl is associated with CI-AKI after CCT.

Some new information has emerged from this study. First, with abnormally severe hyperbilirubinemia (\>1.2 mg/dl), we found that the higher the total bilirubin, the more CI-AKI after CCT, especially \> 2.0 mg/dl of total bilirubin. The renal protection by mild elevations of total bilirubin was all \< 1.2 mg/dl, or within the normal range. Second, the mild elevation of total bilirubin maybe contributed by unconjugated bilirubin rather than by conjugated bilirubin. In patients with total bilirubin \> 2.0mg/dl, mostly due to "patological" hyperbilibubinemia related to cirrhosis or hepatoma. Third, 10% patients without cirrhosis or hepatoma still had their total bilirubin \> 2.0mg/dl, and they still had more CI-AKI after CCT. Total bilirubin \> 2.0mg/dl is therefore an independent risk factor for CI-AKI, which indicated an association between CI-AKI and total bilirubin level \> 2.0mg/dl.

The inciden PC-AKI in patients with total bilirubin\> 2.0 mg/dl was 16.4%. This is the frist sutdy to point out the incidence of PC-AKI regarding hyperbilirubinemia. The incidence of PC-AKI varied from 12 to 50% according to different baseline conditions\[[@pone.0231264.ref002]--[@pone.0231264.ref004], [@pone.0231264.ref044]--[@pone.0231264.ref046]\]. The incidence of PC-AKI in patients with total bilirubin\> 2.0 mg/dl maybe relatively low because of the following reasons. First, we recruited both inpatients and outpatients. Overally, this population was all patients receiveing CCT with relatively mild disease. Most patients had good baseline renal function (66.6% with baseline eGFR\>60 ml/min.1.732m^2^) and without anemia (12.02 g/dl of mean Hb). Only 30.8% patients had DM and shock was only noticed in 4.0% patients. Second, 33.6% patients had cirrhosis and 26.2% patients had hepatoma. Patients with liver disease may have less skeletal muscle mass, which made less creatine storage, followed by less conversion of creatine to creatinine\[[@pone.0231264.ref047]\]. Creatinine-based formula may underestiate renal dysfunction\[[@pone.0231264.ref047]\]. Finally, in this study, we point out the importance of the incidence of PC-AKI in patients with total bilirubin\>2.0 mg/dl. Therefore, without previous studies for comparison, the incidence (16.4%) cannot be considered as too high or too low.

CI-AKI is primarily a condition of glomerular hypotension related to vasoconstriction \[[@pone.0231264.ref048]\]. Biliriun had the ability to neuralize reactive oxidative species(ROS) \[[@pone.0231264.ref049]\]. Increased renal ROS leads renin releases, followed by more secretino of angiotenin II \[[@pone.0231264.ref050]\]. ROS's effect on efferent vasocontriction is reduced\[[@pone.0231264.ref048]\], causing AKI by the reduced intra-glomeurlar pressure. In an animal study, moderate hyperbilirubinemia prevents angiotenin II-dependent hypertension by decreasing vascular oxidative stress \[[@pone.0231264.ref051]\]. The blocked angiotensin II may also reduce vasoconstrction over efferent arterioles \[[@pone.0231264.ref048]\]. Moreover, hyperbilirubinemia may also lower both artery pulse pressure \[[@pone.0231264.ref052]\] and intraglomerula pressure\[[@pone.0231264.ref017]\]. Therefore, severe hyperbilirubinemia may lower pre-renal perfusion by decreassed intraglomerrular perssure, predisposing CI-AKI. Another cause could be direct tubular damages by biliruin. Followed by the condition of pre-renal AKI, CI-AKI is a result of due to tubular injuries. The association between hyperbilirubinemia and AKI in the condition of liver cirrhosis might be partially explained by a direct cytotoxicity and tubular obstruction mediated via bile casts \[[@pone.0231264.ref038], [@pone.0231264.ref053], [@pone.0231264.ref054]\]. Bile cast nephropathy or cholemic nephrosis has been largely forgotten in the modern medical literature, a phenomenon which maybe due to the lack of renal biopsy in most pateints with hyperbilirubinemia.Bile casts are analogous to 'myeloma' or myoglobin casts, as they have direct toxic effects on tubular epithelium with an obstructive capacity, which further predispose contrast related tubular injury in CI-AKI.

There are some limitations in this study. First, because this is a retrospective study, we did not regularly collect direct/indirect bilirubin and iron/ferritin (associated with hemoglobin degradation) before CCT. However, total bilirubin is the most easily obtained data in clinical practice to remind clinicians to avoid CI-AKI. Moreover, it is a novel finding to inform clinicians that hyperbilirubinemia is an independent risk factor for CI-AKI in addition to patients with liver dysfunction. In particular, patients with total bilirubin\> 2 mg/dl without baseline liver conditions are easily missed. We highlight this strong association based on current data. If no data of bilirubin, we should also check icteric sclera in our daily practice. More detailed role of direct or indirect bilirubin on renal function after contrast exposure needs further studies in the future. Second, the mechanism of direct injury by severe hyperbilirubinemia in CI-AKI remains to be explored.

Conclusions {#sec013}
===========

We reported here for the first time, evidence that severe hyperbilirubinemia (total bilirubin \> 2.0 mg/dl) is an independent risk factor for CI-AKI, dialysis and mortality after CCT. Most patients with total bilirubin \> 2.0mg/dl also had cirrhosis or hepatoma. Clinicians should identify total bilirubin\>2.0mg/dl even without cirrhosis or hepatoma.

Supporting information {#sec014}
======================
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� Hepatoma and cirrhosis are strongly associated with high bilirubin levels and AKI. To show that high bilirubin is an independent risk factor, the authors should also show the incidence of CI-AKI as for figure 2A but only in the 10% patients with high serum total bilirubin levels and no hepatoma or cirrhosis compared to \<1.2 and 1.3-2 mg/dl groups

Thanks for this comment. We re-analyzed this special group (only 10%, without cirrhosis or HCC). We added two more tables in the supplementary file, as table 2 and table 3.

Supplementary table 2. Baseline characteristics of patients with total bilirubin\> 2mg /dl (n=1368) divided to liver conditions.

Supplementary table 3 Baseline characteristics of patients without cirrhosis or hepatoma (n=7826) divided to three levels of total bilirubin

In supplementary table 3, the incidences of post-contrast AKI in patients without any liver conditions in three different total bilirubin levels were: 8.1% vs. 9.6% vs. 13.4 (p\<0.001). We drew this outcome in a new figure 4C to point out the importance of total bilirubin level of all clinical conditions. The result can point out the importance the independent role of total bilirubin \>2 on post-contrast AKI.

Thanks for your comments.

� What are the serum levels of conjugated (direct) and unconjugated (indirect) bilirubin? These data can also be informative regarding potential bilirubin conjugation issues leading to CI-AKI.

Thanks for this comment. Because this is a retrospective study, we did not regularly collect direct/indirect bilirubin and iron/ferritin (associated with hemoglobin degradation) before contrast-enhanced computed tomography. Indeed, this is a major limitation to our study and we wrote it in the final part of discussion. However, even only with total bilirubin, we can still speculate that there is a merit of this study because of large case numbers and very strong statistical significance after adjusting all comorbidities and laboratory data. In addition, total bilirubin is the most easily obtained data in clinical practice to remind clinicians to avoid contrast related AKI. Moreover, it is a novel finding to inform clinicians that hyperbilirubinemia is an independent risk factor for contrast related AKI in addition to patients with liver dysfunction. This is beyond everyone's expectation and this point out the importance of this study. We highlight this strong association based on current data. Besides, if no data of bilirubin, we should also check icteric sclera in our daily practice. More detailed role of direct or indirect bilirubin on renal function after contrast exposure will be elucidated in our later study. We added the above explanations in the final part of discussion.

� What are the iron and ferritin levels? Are they associated with CI-AKI?

Thanks for your comment. We did not have the data of iron and ferritin because this is a retrospective study. In clinical practice, we did not check iron and ferritin because contrast-enhanced computed tomography. Iron and ferritin levels were associated with hemoglobin degradation, which is suggestive of direct/indirect bilirubin, we will study this part in the later study.

� This manuscript was also difficult to follow since the figures are not numbered, figure legends of 3 and 4 are inverted. There are also many syntax and typos errors.

Sorry for this typo. We exchange figure 3 and figure 4.

1\. Hepatoma and cirrhosis are strongly associated with high bilirubin levels and AKI. To show that high bilirubin is an independent risk factor, the authors should also show the incidence of CI-AKI as for figure 2A but only in the 10% patients with high serum total bilirubin levels and no hepatoma or cirrhosis compared to \<1.2 and 1.3-2 mg/dl groups.

Thanks for this comment. We re-analyzed this special group (only 10%, without cirrhosis or HCC). We added two more tables in the supplementary file, as table 2 and table 3.

Supplementary table 2. Baseline characteristics of patients with total bilirubin\> 2mg /dl (n=1368) divided to liver conditions.

Supplementary table 3 Baseline characteristics of patients without cirrhosis or hepatoma (n=7826) divided to three levels of total bilirubin

In supplementary table 3, the incidences of post-contrast AKI in patients without any liver conditions in three different total bilirubin levels were: 8.1% vs. 9.6% vs. 13.4 (p\<0.001). We drew this outcome in a new figure 4C to point out the importance of total bilirubin level of all clinical conditions. The result can point out the importance the independent role of total bilirubin \>2 on post-contrast AKI.

Thanks for your comments.

2\. This study suggests that patients with high serum total bilirubin levels have a higher risk of CI-AKI of which 16.4% of the patients has developed CI-AKI in this group. Can the authors speculate in the discussion on why a large portion of patients in this group did not develop CI-AKI while others did?

Because of the incidence of PC-AKI varied according to different baseline conditions. The incidence of PC-AKI in patients with total bilirubin\>2.0 mg/dl cannot be considered as too high or too low. The incidence PC-AKI in patients with total bilirubin\> 2.0 mg/dl was 16.4%. This is the first study to point out the incidence of PC-AKI regarding hyperbilirubinemia. The incidence of PC-AKI varied from 12 to 50% according to different baseline conditions \[2-4, 44-46\]. The incidence of PC-AKI in patients with total bilirubin\> 2.0 mg/dl maybe relatively low because of the following reasons. First, we recruited both inpatients and outpatients. Overall, this population was all patients receiving CCT with relatively mild disease. Most patients had good baseline renal function (66.6% with baseline eGFR\>60 ml/min.1.732m2) and without anemia (12.02 g/dl of mean Hb). Only 30.8% patients had DM and shock was only noticed in 4.0% patients. Second, 33.6% patients had cirrhosis and 26.2% patients had hepatoma. Patients with liver disease may have less skeletal muscle mass, which made less creatine storage, followed by less conversion of creatine to creatinine\[47\]. Creatinine-based formula may underestimate renal dysfunction\[47\]. Finally, this is the first study to mention the incidence of PC-AKI in patients with total bilirubin\>2.0 mg/dl. Therefore, without previous studies for comparison, the incidence (16.4%) cannot be considered as too high or too low.

We added this discussion in the part of discussion. Thanks for your comment.

3\. Mechanistically, the major source of bilirubin is from heme after hemoglobin degradation. This bilirubin circulates with serum albumin (unconjugated) while the liver conjugates bilirubin to make it soluble for excretion into the bile. The free bilirubin (unconjugated) is the bilirubin that is contributing the most to the effect associated with bilirubin. As such, one missing piece to better understand the protective or deleterious role of bilirubin is the free vs conjugated bilirubin levels. What are the serum levels of conjugated (direct) and unconjugated (indirect) bilirubin? These data can also be informative regarding potential bilirubin conjugation issues leading to CI-AKI. Along this line, heme is metabolized by heme oxygenase into biliverdin before being converted into bilirubin. These processes release Iron and Carbon monoxide which could reflect also a defect in Heme oxygenase activity. Thus, what are the iron and ferritin levels? Are they associated with CI-AKI?

Thanks for this comment. Because this is a retrospective study, we did not regularly collect direct/indirect bilirubin and iron/ferritin (associated with hemoglobin degradation) before contrast-enhanced computed tomography. Indeed, this is a major limitation to our study and we wrote it in the final part of discussion. However, even only with total bilirubin, we can still speculate that there is a merit of this study because of large case numbers and very strong statistical significance after adjusting all comorbidities and laboratory data. In addition, total bilirubin is the most easily obtained data in clinical practice to remind clinicians to avoid contrast related AKI. Moreover, it is a novel finding to inform clinicians that hyperbilirubinemia is an independent risk factor for contrast related AKI in addition to patients with liver dysfunction. This is beyond everyone's expectation and this point out the importance of this study. Besides, if no data of bilirubin, we should also check icteric sclera in our daily practice. We highlight this strong association based on current data. More detailed role of direct or indirect bilirubin on renal function after contrast exposure will be elucidated in our later study. We added the above explanations in the final part of discussion.

Minor concerns:

In the discussion, the link between PKC and bilirubin and how it is relevant for the present manuscript is not clear.

We discussed it because these were studies about the protective function of bilirubin based on protein kinase C (PKC) \[Diabetes. 1998;47(6):859-66. American journal of nephrology. 1998;18(4):344-50. Arteriosclerosis, thrombosis, and vascular biology. 1997;17(5):969-78\]. However, as your comment, the link was weak and these studies were published many years ago. Thus, we deleted this discussion about the PKC.
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PLOS ONE

Dear author,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please correct/explain the different in the number of patients as noted by the reviewer.

We would appreciate receiving your revised manuscript by Apr 26 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Olivier Barbier

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Please correct/explain the different in the number of patients as noted by the reviewer.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

17 Mar 2020

1.There is a mismatch in the numbers of patients without liver conditions (in the 10% as stated in figure 3). The total number of patients with bilirubin ≥ 2 is n = 1670 page 22 while in the new supplementary table 2 total number of patients with bilirubin ≥ 2 n = 1368. Why is that?

Case numbers with different liver conditions were as follows,

� All patients (n=9496): cirrhosis only (n=659), hepatoma only (n=443), both cirrhosis and hepatoma (n=568), and no cirrhosis no hepatoma (n=7826)

� Patients with total bilirubin\> 2mg/dl (n=1368): cirrhosis only (n=224), hepatoma only (n=123), both cirrhosis and hepatoma (n=235), and no cirrhosis no hepatoma (n=786)

Therefore, "1670" is cirrhosis only (n=659)+hepatoma only (n=443)+both cirrhosis and hepatoma (n=568) in all patients. We revised the figure legnds of figure 3. Also, we added a supplementary figure 2 (2A for all patients and 2B for patients with total bilirubin\>2 mg/dl) .

2.There are still many typos and syntax errors.

�We revised all text carefully.

3\. This section "However, even only with total bilirubin, we can still speculate that there is a merit of this study because of large case numbers and very strong statistical significance after adjusting all comorbidities and laboratory data." should be removed from the discussion and the authors should let the readers judge the strength of the manuscript based solely on the data provided.

�According to your suggestion, we deleted it.

4.All the sections added in the revised manuscript on pages 17-18 should be re-write for a scientific manuscript discussion not as a response to reviewers.

The discussion should be modified accordingly.

� We re-wrote and revised this part. Thanks for your comment.

Other minors comments:

The authors should decrease the use of "this is the first study". It is repetitive and unnecessary.

�We decreaed this sentence according to your suggestion.

Page 18: "Second, the mechanism of direct injury by severe hyperbilirubinemia in CI-AKI remains to be explored. The biological mechanism needs more preclinical studies in the future." This is redundant...

�We deleted "The biological mechanism needs more preclinical studies in the future"

Support of this manuscript: This study was funded by grant TCVGH-1063601B and TCVGH-1073604C from Taichung Veterans General Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript
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Dear Dr. Shang-Feng Tsai,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Olivier Barbier

Academic Editor

PLOS ONE
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Severe hyperbilirubinemia is associated with higher risk of contrast-related acute kidney injury following contrast-enhanced computed tomography

Dear Dr. Tsai:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Olivier Barbier

Academic Editor

PLOS ONE
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